# Parkinson's Pathways

> A free, family-friendly guide to every recruiting Parkinson's disease clinical trial. Currently tracking 569 trials.

## About

Parkinson's Pathways helps patients, caregivers, and clinicians find and understand Parkinson's clinical trials. Every trial is translated for families with a five-word goal, eligibility details, and nearby locations.

Two distinct content tiers are exposed here:

1. **PD Curated** — Parkinson's-only trials with AI-generated family-friendly summaries, five-word goals, geocoded sites, and recent site-change tracking.
2. **Universal Raw Mirror** — A larger, condition-agnostic mirror of ClinicalTrials.gov with no AI summaries and no editorial enrichment. Use this when you need source-of-truth raw data.

Selected content families expose clean Markdown twins (append `.md` to the URL) with YAML frontmatter, intended for LLM ingestion. Supported patterns: `/learn/{slug}.md`, `/trial/{nctId}.md`, `/trials-near-me.md`, `/trials-near-me/{city}.md`, `/trials/{type}/{slug}.md`, `/trials/eu/{euctId}.md`. Pages such as `/`, `/about`, `/trials`, `/insights`, `/match`, and `/digest` do not have Markdown twins.

## Key Pages

- [Browse All Trials](https://parkinsonspathways.com/trials): Search and filter all 569 recruiting Parkinson's clinical trials by phase, study type, enrollment size, country, and age eligibility.
- [Trials Near Me](https://parkinsonspathways.com/trials-near-me): Find clinical trials near a specific location using zip code or city search.
- [Insights Dashboard](https://parkinsonspathways.com/insights): Visual overview of the Parkinson's trial landscape, including phase breakdown, intervention types, top sponsors, eligibility stats, and a global map.
- [Learn](https://parkinsonspathways.com/learn): Educational articles explaining clinical trial concepts, translated for families.
- [About](https://parkinsonspathways.com/about): The story behind the project and how it works.

## PD Curated — Learn Articles (Markdown twins)

Each article is available as both HTML (for humans) and Markdown (for LLM ingestion). Markdown URLs include YAML frontmatter with title, description, canonical URL, and publication date.

- Why I Built Parkinson's Pathways — HTML: https://parkinsonspathways.com/learn/why-i-built-parkinsons-pathways — Markdown: https://parkinsonspathways.com/learn/why-i-built-parkinsons-pathways.md
- What Do Clinical Trial Phases Mean? — HTML: https://parkinsonspathways.com/learn/what-do-clinical-trial-phases-mean — Markdown: https://parkinsonspathways.com/learn/what-do-clinical-trial-phases-mean.md
- What Do Clinical Trial Statuses Mean? — HTML: https://parkinsonspathways.com/learn/what-do-clinical-trial-statuses-mean — Markdown: https://parkinsonspathways.com/learn/what-do-clinical-trial-statuses-mean.md
- How Long Does a Parkinson's Clinical Trial Last? — HTML: https://parkinsonspathways.com/learn/how-long-does-a-parkinsons-clinical-trial-last — Markdown: https://parkinsonspathways.com/learn/how-long-does-a-parkinsons-clinical-trial-last.md
- How to Talk to Your Neurologist About Clinical Trials — HTML: https://parkinsonspathways.com/learn/how-to-talk-to-your-neurologist-about-clinical-trials — Markdown: https://parkinsonspathways.com/learn/how-to-talk-to-your-neurologist-about-clinical-trials.md
- How to Spot a Questionable Clinical Trial — HTML: https://parkinsonspathways.com/learn/how-to-spot-a-questionable-clinical-trial — Markdown: https://parkinsonspathways.com/learn/how-to-spot-a-questionable-clinical-trial.md
- Just Diagnosed with Parkinson's? Where to Start with Clinical Trials — HTML: https://parkinsonspathways.com/learn/just-diagnosed-with-parkinsons-clinical-trials — Markdown: https://parkinsonspathways.com/learn/just-diagnosed-with-parkinsons-clinical-trials.md
- Stem Cell Therapy for Parkinson's: What You Should Actually Know — HTML: https://parkinsonspathways.com/learn/stem-cell-therapy-for-parkinsons — Markdown: https://parkinsonspathways.com/learn/stem-cell-therapy-for-parkinsons.md
- Will My Family Member Get a Placebo? — HTML: https://parkinsonspathways.com/learn/will-my-family-member-get-a-placebo — Markdown: https://parkinsonspathways.com/learn/will-my-family-member-get-a-placebo.md
- How Close Is a Cure for Parkinson's Disease? — HTML: https://parkinsonspathways.com/learn/how-close-is-a-cure-for-parkinsons — Markdown: https://parkinsonspathways.com/learn/how-close-is-a-cure-for-parkinsons.md
- Parkinson's and Dementia: Clinical Trials Families Should Know — HTML: https://parkinsonspathways.com/learn/parkinsons-and-dementia-clinical-trials — Markdown: https://parkinsonspathways.com/learn/parkinsons-and-dementia-clinical-trials.md
- What Is Levodopa and How Does It Work? — HTML: https://parkinsonspathways.com/learn/what-is-levodopa-and-how-does-it-work — Markdown: https://parkinsonspathways.com/learn/what-is-levodopa-and-how-does-it-work.md
- What to Expect in the First Year After Diagnosis — HTML: https://parkinsonspathways.com/learn/what-to-expect-first-year-after-parkinsons-diagnosis — Markdown: https://parkinsonspathways.com/learn/what-to-expect-first-year-after-parkinsons-diagnosis.md
- Diet and Parkinson's Risk: What the Research Says — HTML: https://parkinsonspathways.com/learn/diet-and-parkinsons-risk — Markdown: https://parkinsonspathways.com/learn/diet-and-parkinsons-risk.md
- ClinicalTrials.gov vs Parkinson's Pathways — HTML: https://parkinsonspathways.com/learn/clinicaltrials-gov-vs-parkinsons-pathways — Markdown: https://parkinsonspathways.com/learn/clinicaltrials-gov-vs-parkinsons-pathways.md
- Interventional vs Observational Parkinson's Trials — HTML: https://parkinsonspathways.com/learn/interventional-vs-observational-parkinsons-trials — Markdown: https://parkinsonspathways.com/learn/interventional-vs-observational-parkinsons-trials.md
- Phase 1 vs Phase 2 vs Phase 3 Trials — HTML: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials — Markdown: https://parkinsonspathways.com/learn/phase-1-vs-phase-2-vs-phase-3-trials.md
- Disease-Modifying vs Symptomatic Parkinson's Trials — HTML: https://parkinsonspathways.com/learn/disease-modifying-vs-symptomatic-parkinsons-trials — Markdown: https://parkinsonspathways.com/learn/disease-modifying-vs-symptomatic-parkinsons-trials.md
- Industry-Sponsored vs Academic Parkinson's Trials — HTML: https://parkinsonspathways.com/learn/industry-sponsored-vs-academic-parkinsons-trials — Markdown: https://parkinsonspathways.com/learn/industry-sponsored-vs-academic-parkinsons-trials.md
- Clinical Trial vs Standard of Care — HTML: https://parkinsonspathways.com/learn/clinical-trial-vs-standard-of-care-parkinsons — Markdown: https://parkinsonspathways.com/learn/clinical-trial-vs-standard-of-care-parkinsons.md
- dbs-vs-duopa-vs-focused-ultrasound-parkinsons — HTML: https://parkinsonspathways.com/learn/dbs-vs-duopa-vs-focused-ultrasound-parkinsons — Markdown: https://parkinsonspathways.com/learn/dbs-vs-duopa-vs-focused-ultrasound-parkinsons.md
- parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa — HTML: https://parkinsonspathways.com/learn/parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa — Markdown: https://parkinsonspathways.com/learn/parkinsons-vs-lewy-body-dementia-vs-psp-vs-msa.md
- parkinsons-vs-essential-tremor — HTML: https://parkinsonspathways.com/learn/parkinsons-vs-essential-tremor — Markdown: https://parkinsonspathways.com/learn/parkinsons-vs-essential-tremor.md
- levodopa-vs-dopamine-agonists — HTML: https://parkinsonspathways.com/learn/levodopa-vs-dopamine-agonists — Markdown: https://parkinsonspathways.com/learn/levodopa-vs-dopamine-agonists.md
- carbidopa-levodopa-formulations-compared — HTML: https://parkinsonspathways.com/learn/carbidopa-levodopa-formulations-compared — Markdown: https://parkinsonspathways.com/learn/carbidopa-levodopa-formulations-compared.md
- glp1-drugs-parkinsons-research — HTML: https://parkinsonspathways.com/learn/glp1-drugs-parkinsons-research — Markdown: https://parkinsonspathways.com/learn/glp1-drugs-parkinsons-research.md
- tavapadon-new-parkinsons-drug-2026 — HTML: https://parkinsonspathways.com/learn/tavapadon-new-parkinsons-drug-2026 — Markdown: https://parkinsonspathways.com/learn/tavapadon-new-parkinsons-drug-2026.md
- state-of-parkinsons-clinical-trials — HTML: https://parkinsonspathways.com/learn/state-of-parkinsons-clinical-trials — Markdown: https://parkinsonspathways.com/learn/state-of-parkinsons-clinical-trials.md
- where-parkinsons-clinical-trials-happen — HTML: https://parkinsonspathways.com/learn/where-parkinsons-clinical-trials-happen — Markdown: https://parkinsonspathways.com/learn/where-parkinsons-clinical-trials-happen.md

## PD Curated — Trial Pages (Markdown twins)

Every recruiting Parkinson's trial has a Markdown twin at `/trial/{nctId}.md` containing the AI summary, five-word goal, plain-language eligibility, geocoded sites, contact info, and recent site changes (last 30 days). Append `.md` to any `/trial/{nctId}` URL in the sitemap to reach its twin; below are the 50 most recently updated for quick discovery.

- A study to improve the delivery of AB-1005 gene therapy into the brain (EUCT-2025-522441-21-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-522441-21-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-522441-21-00.md
- A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease. (EUCT-2024-516888-84-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-516888-84-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-516888-84-00.md
- Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD (EUCT-2024-516610-38-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-516610-38-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-516610-38-00.md
- Multicenter, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease. (EUCT-2024-510959-35-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-510959-35-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-510959-35-00.md
- Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers (EUCT-2026-525448-14-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2026-525448-14-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2026-525448-14-00.md
- Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DIVE-Follow up) (EUCT-2025-522261-30-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-522261-30-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-522261-30-00.md
- Accurately diagnose Lewy body dementia (NCT06120049) — HTML: https://parkinsonspathways.com/trial/NCT06120049 — Markdown: https://parkinsonspathways.com/trial/NCT06120049.md
- Detect brain alpha synuclein deposits (NCT06891703) — HTML: https://parkinsonspathways.com/trial/NCT06891703 — Markdown: https://parkinsonspathways.com/trial/NCT06891703.md
- Measure heat shock protein levels (NCT07380204) — HTML: https://parkinsonspathways.com/trial/NCT07380204 — Markdown: https://parkinsonspathways.com/trial/NCT07380204.md
- Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy (EUCT-2023-508718-40-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-508718-40-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-508718-40-00.md
- Effect of Exenatide on disease progression in early Parkinson’s disease. (EUCT-2024-520069-30-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-520069-30-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-520069-30-00.md
- Assessment of clozapine-related immunodeficiency effect in Parkinson's disease patients (CLOZIDPD) (EUCT-2024-514530-21-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-514530-21-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-514530-21-00.md
- A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease (EUCT-2024-517310-15-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-517310-15-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-517310-15-00.md
- GRoningen Early-PD Ambroxol Treatment Pharmacokinetics (EUCT-2024-519088-16-01) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-519088-16-01 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-519088-16-01.md
- Cognitive effects of methylphenidate in patients with Parkinson's disease with mild cognitive impairment. (EUCT-2026-525701-12-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2026-525701-12-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2026-525701-12-00.md
- CNS penetration and target engagement of Mirivadelgat in Parkinson’s disease (EUCT-2025-523570-17-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-523570-17-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523570-17-00.md
- Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled phase II trial (EUCT-2023-504278-39-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-504278-39-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-504278-39-00.md
- A trial to determine the safety and tolerability of transplanted stem cellderived dopamine neurons to the brains of individuals with Parkinson's Disease. (EUCT-2024-511237-35-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-511237-35-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511237-35-00.md
- A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's Disease (EUCT-2022-502207-30-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2022-502207-30-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2022-502207-30-00.md
- Patient- and care-related benefits of amyloid PET imaging (ENABLE) (EUCT-2023-503705-10-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-503705-10-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-503705-10-00.md
- PsyPal; Psilocybin Therapy for Psychological Distress in Palliative Patients (EUCT-2023-510488-36-01) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-510488-36-01 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-510488-36-01.md
- A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study (EUCT-2025-521772-57-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-521772-57-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-521772-57-00.md
- A study to find how well LY3884961 works and how safe it is in participants with Parkinson’s disease (EUCT-2024-519587-40-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-519587-40-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-519587-40-00.md
- A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinson’s disease and in Patients with Multiple System Atrophy (EUCT-2024-511222-30-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-511222-30-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511222-30-00.md
- Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease (EUCT-2024-518865-85-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-518865-85-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-518865-85-00.md
- An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson’s disease (EUCT-2022-500292-31-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2022-500292-31-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2022-500292-31-00.md
- Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS (EUCT-2025-523872-22-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-523872-22-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523872-22-00.md
- Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD) (EUCT-2024-517413-33-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-517413-33-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-517413-33-00.md
- Clinical trial to investigate the adherence of a new Rotigotine patch to the skin of patients with Parkinson’s disease (EUCT-2025-521172-64-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-521172-64-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-521172-64-00.md
- A study to learn more about the long-term safety and efficacy of AB-1005 gene therapy in people with Parkinson’s disease or multiple system atrophy (EUCT-2025-522653-19-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-522653-19-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-522653-19-00.md
- Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE) (EUCT-2026-525906-37-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2026-525906-37-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2026-525906-37-00.md
- Pathophysiology of pain in Parkinson's disease: exploration of the serotonin system in positron emission tomography (EUCT-2022-501123-24-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2022-501123-24-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2022-501123-24-00.md
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Parkinson’s Disease (EUCT-2023-504412-14-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-504412-14-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-504412-14-00.md
- Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) (EUCT-2024-513384-15-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-513384-15-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-513384-15-00.md
- A study to find out how healthy people tolerate a new drug called S221237. (EUCT-2024-519381-53-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-519381-53-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-519381-53-00.md
- A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson's disease (BouNDless) (EUCT-2024-511940-20-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-511940-20-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-511940-20-00.md
- Lu AF28996 in Patients With Parkinson's Disease (EUCT-2023-507785-12-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-507785-12-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-507785-12-00.md
- A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Days are Tolerated in the Body (EUCT-2025-523612-37-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-523612-37-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-523612-37-00.md
- Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design. (EUCT-2024-512311-41-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-512311-41-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-512311-41-00.md
- New drug to slow Parkinson (NCT04691661) — HTML: https://parkinsonspathways.com/trial/NCT04691661 — Markdown: https://parkinsonspathways.com/trial/NCT04691661.md
- Slow early Parkinson disease progression (NCT06680830) — HTML: https://parkinsonspathways.com/trial/NCT06680830 — Markdown: https://parkinsonspathways.com/trial/NCT06680830.md
- An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging pathological alpha-synuclein deposition in the brains of patients with Parkinson’s disease (PD) or Multiple System Atrophy (MSA) compared to age-matched healthy controls (AMHC) (EUCT-2023-506965-72-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2023-506965-72-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2023-506965-72-00.md
- A Study of Suvecaltamide in Adults with Moderate to Severe Residual Tremor in Parkinson's Disease (EUCT-2024-515177-94-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-515177-94-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-515177-94-00.md
- Slow early Parkinson disease progression (NCT07174310) — HTML: https://parkinsonspathways.com/trial/NCT07174310 — Markdown: https://parkinsonspathways.com/trial/NCT07174310.md
- New medication slows Parkinson progression (NCT06976268) — HTML: https://parkinsonspathways.com/trial/NCT06976268 — Markdown: https://parkinsonspathways.com/trial/NCT06976268.md
- A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson’s Disease (BeyoND) (EUCT-2024-513548-27-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-513548-27-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-513548-27-00.md
- TADalafil in early-stage Parkinson’s Disease (TAD-PD) (EUCT-2025-521819-39-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2025-521819-39-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2025-521819-39-00.md
- Test safety of spinal medication (NCT06565195) — HTML: https://parkinsonspathways.com/trial/NCT06565195 — Markdown: https://parkinsonspathways.com/trial/NCT06565195.md
- GREAT; GRoningen Early-PD Ambroxol Treatment Trial (EUCT-2024-514976-41-00) — HTML: https://parkinsonspathways.com/trial/EUCT-2024-514976-41-00 — Markdown: https://parkinsonspathways.com/trial/EUCT-2024-514976-41-00.md
- Reduce harmful brain protein levels (NCT07216066) — HTML: https://parkinsonspathways.com/trial/NCT07216066 — Markdown: https://parkinsonspathways.com/trial/NCT07216066.md

## Universal Raw Mirror (any condition)

A separate, condition-agnostic mirror of ClinicalTrials.gov. **Raw data only — no AI summaries, no PD-specific filtering, no editorial enrichment.** Use this when you want source-of-truth data with field-level change tracking.

- URL pattern: https://parkinsonspathways.com/agent/trials/{nctId}.md
- Authoritative source: https://clinicaltrials.gov/study/{nctId}

## Agent API

A programmatic API namespace for agents and downstream services is in the works. Entry point will live at `https://parkinsonspathways.com/api/agent/` and will expose change feeds, matching, and replay endpoints. Until that ships, retrieve content via the Markdown URLs above.

## Machine-Readable Resources

- [Sitemap](https://parkinsonspathways.com/sitemap.xml) — clean HTML URLs for every public page (only `/trial/{nctId}`, `/learn/{slug}`, `/trials-near-me`, `/trials-near-me/{city}`, `/trials/{type}/{slug}`, and `/trials/eu/{euctId}` entries support a `.md` twin)
- [Sitemap Index](https://parkinsonspathways.com/sitemap-index.xml) — references the main sitemap
- [Full LLM Context](https://parkinsonspathways.com/llms-full.txt)